Field trials with oxamniquine in a Schistosomiasis mansoni-endemic area.
In Peri-Peri (Minas Gerais), an area endemic for Schistosoma mansoni, 591 inhabitants were examined. A coprological survey showed a prevalence of infection of 43.7%. After clinical examination 220 patients were distributed into three groups for treatment with oxamniquine; in Group 1, 19 children (2 to 15 years) were treated with a single oral dose of drug suspension around 20 mg/kg body weight; in Group 2, 47 children were treated orally with two 10 mg/kg doses with a 6- to 8-hour interval between them; in Group 3, 154 adults were treated with a single dose of about 15 mg/kg (capsules). The most frequent side effects were dizziness, drowsiness, and headache. No statistical difference in frequency of side effects was observed between Groups 1 and 2. Nevertheless, after treatment 32% of the patients in Group 1 complained of dizziness and 13% of headache, whereas in Group 2 the frequencies of these symptoms were 2% and 0%, respectively. Adults (Group 3) had a higher frequency of side effects, their chief complaints being dizziness and drowsiness. In Groups 1, 2, and 3, respectively, 73.7%, 62.2%, and 82.4% of the patients were cured. Statistical analysis did not show any difference in cure rates between children in Groups 1 and 2; however a significance was found when compared with the cure rate observed in adults, showing the drug to be more active in the latter group. In 61.8% of the 40 patients not cured a decrease of over 90% in the number of S. mansoni eggs/g feces was observed. From the data above oxamniquine seems to be an effective schistosomicidal drug suitable for use in endemic areas, although further studies are still needed.
D000293:Adolescent; D000818:Animals; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D004197:Disease Reservoirs; D004361:Drug Tolerance; D006261:Headache / Q000139:chemically induced; D006801:Humans; D009600:Nitroquinolines / Q000627:therapeutic use*; D010073:Oxamniquine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced
D009600:Nitroquinolines; D010073:Oxamniquine